NCT06049966View on ClinicalTrials.gov

Atezolizumab in Large Cell Neuroendocrine Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

August 1, 2022

Study Completion Date

May 1, 2023

Conditions
Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
DRUG

Atezolizumab

TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML

DRUG

Carboplatin

SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML

DRUG

Etoposide

ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML

Trial Locations (2)

11527

National and Kapodistrian University of Athens, Athens

OCEBER, Athens

All Listed Sponsors
lead

Oncology Center of Biochemical Education And Research

OTHER

NCT06049966 - Atezolizumab in Large Cell Neuroendocrine Carcinoma | Biotech Hunter | Biotech Hunter